Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients
Condition(s):EBV Viremia; CMV ViremiaLast Updated:November 1, 2019Completed
Hide Studies Not Open or Pending
Condition(s):EBV Viremia; CMV ViremiaLast Updated:November 1, 2019Completed
Condition(s):Congenital Cytomegalovirus InfectionLast Updated:January 26, 2023Terminated
Condition(s):Idiopathic Pulmonary FibrosisLast Updated:April 29, 2022Completed
Condition(s):Nasopharyngeal Carcinoma; EBV-Related Gastric Carcinoma; EBV-Related Leiomyosarcoma; EBV Related Carcinoma; EBV-Related SarcomaLast Updated:March 28, 2024Recruiting
Condition(s):Epstein-Barr Virus Associated Lymphoma; Lymphoproliferative DisordersLast Updated:March 5, 2024Completed
Condition(s):Congenital Cytomegalovirus Infection; Sensorineural Hearing LossLast Updated:June 3, 2021Completed
Condition(s):Kidney TransplantLast Updated:December 17, 2015Terminated
Condition(s):Cytomegalovirus DiseaseLast Updated:July 16, 2021Terminated
Condition(s):Cytomegalovirus Disease; Kidney Transplant InfectionLast Updated:July 16, 2021Terminated
Condition(s):Bone Marrow Transplantation; CytomegalovirusLast Updated:April 21, 2015Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.